Thomas Becker, Bastian Ringe, Miguel Nyibata, Andreas Meyer zu Vilsendorf, Harald Schrem, Rainer L?ck, Michael Neipp, J?rgen Klempnauer, Hueseyin Bektas
Context In clinical pancreas transplantation the choice of preservation solution may have an impact on graft pancreatitis. Experience with histidine-tryptophan-ketoglutarate (HTK) is still limited whereas University of Wisconsin (UW) solution is currently the preferred perfusate worldwide. Objective The aim of this study was to analyze our experience with HTK in pancreas transplantation. Participants In a retrospective analysis, data from 95 primary simultaneous pancreaskidney transplantations were reviewed. The use of HTK (n=48) and UW (n=47) solution was stratified into two groups. Main outcome measures Patient/graft survival and early graft function were compared. Results No significant differences between 1, 3 and 12 month patient survival (HTK: 97.9%, 97.9%, and 95.7% vs. UW: 95.7%, 89.4%, and 89.4%, respectively), and pancreas graft survival (HTK: 87.5%, 87.5%, and 85.4% vs. UW: 87.0%, 82.6%, and 82.6%, respectively) were detected. Higher values for peak lipase were observed on day 1 in the HTK group (not reaching significance: P=0.131) whereas no differences were noted for amylase and C-reactive protein. Conclusions HTK is clinically comparable to UW. Both solutions have been shown to be safe for pancreas preservation. Successful pancreas transplantation depends on many factors such as donor and recipient factors, but skilled organ procurement techniques, organ preservation, and transplant experience in this field is mandatory. The choice of organ preservation solution is only one point in this context.
